

Drug for Parkinson's disease

Drug	Uses	Pharmacokinetics	Side effect	Drug interaction	Contraindication
<p>Levodopa (L-dopa)</p>	<p>1-Precursor of dopamine 2-First line treatment 3-used combined with carbidopa (Peripheral dopa decarboxylase inhibitor): *To inhibit peripheral conversion of L-dopa to dopamine *To decrease metabolism of L-dopa in GIT and peripheral tissues, Thus,increasing t_{1/2}. *To increase availability of levodopa. *To reduce dose of levodopa and side effects. *Do not cross BBB. -Note: L-Dopa Ameliorates the signs of Parkinsonism particularly bradykinesia But does not cure the disease.</p>	<p>1-absorbed from the small intestine by active transport. 2-Ingestion of meal especially high protein meal interferes with absorption and transport into CNS (taken on empty stomach). 3- Short duration of action t_{1/2}= 1-2 h (fluctuation of plasma concentration).</p>	<p>1-On-off phenomenon (Off= akinesia or hypomobility) phenomenon (Rx MAOI-B & low protein diet). 2-Wearing-off effect (duration of “on” states becomes shorter). 3-Dyskinesia (involuntary movements occurs in 40 to 90% of patients) due to fluctuating plasma levels of levodopa and the presence of hypersensitive dopamine receptors. 4-<u>Peripheral effects:</u> *Anorexia, nausea, and vomiting (due to stimulation of emetic center). *Mydriasis, orthostatic hypotension, cardiac arrhythmias. 5-<u>CNS effects:</u> (Psychological disorders) mainly psychosis, delusions, hallucinations, confusion, sleep disturbances and depression.</p>	<p>1-Proteins ingested with meals. 2-Pyridoxine (Vitamin B6) bez it diminished the effect of the drug due to increased peripheral metabolism. 3-Nonselective MAO inhibitors (phenelzine) it will cause hypertensive crisis due to increased catecholamines (NE).</p>	<p>1-Psychotic patient. 2-Closed angle glaucoma (due to mydriatic effect). 3-Patients with history of melanoma Why? Bez L-dopa is a precursor of melanin.</p>

<p>Amantadine</p>	<p>1-originally introduced as an antiviral. 2- Amantadine increases dopamine release. 3-Acts as an antagonist at muscarinic and NMDA (<i>N-methyl-D-aspartate</i>) receptors. 4- modestly effective in treating symptoms of parkinsonism but last only for short period (few weeks) and only used for L-Dopa resistance.</p>	<p>1-given orally with short half life. 2-most of the drug being excreted unchanged in the urine.</p>	<p>1-Nausea, anxiety, insomnia, confusion, hallucinations (dopamine like side effects). 2-Dry mouth, urinary retention (anticholinergic effects). 3-Restlessness and hallucinations (NMDA antagonist).</p>		
<p>Dopamine receptor agonists</p>	<p>➤ Ergot derivatives Bromocriptine ➤ Non ergot derivatives Pramipexole 1-Dopamine agonists are used in advanced Parkinson's disease with fluctuation and dyskinesia.</p> <p><u>Bromocriptine</u> 1-Bromocriptine, an ergot derivative, is an agonist at D2-receptors. 2-Rx of hyperprolactinemia (<i>galactorrhea</i>) 3-Rx of infertility in women.</p> <p><u>Pramipexole</u> 1-Non Ergot dopamine agonist 2-Used alone or in combination with L-Dopa. 3-Has the advantage of being free radicals scavenger.</p>	<p>1-Have longer duration of action than L-dopa (<i>less likely to cause dyskinesias than levodopa</i>)</p> <p><u>Bromocriptine</u> 1-Is given orally, short t_{1/2}.</p>	<p><u>Bromocriptine</u> 1-Nausea, vomiting, postural hypotension 2-Confusion, hallucinations, delusions 3-Dyskinesias (<i>less prominent</i>). 4-To minimize adverse effects, the dose is built up slowly over 2 or 3 months.</p> <p><u>Pramipexole</u> 1-similar to L-Dopa, but less dyskinesias.</p>		<p><u>Bromocriptine</u> 1-Psychosis 2-Peripheral vascular disease 3-Recent myocardial infarction</p>

Selegiline

1-Selegiline is an irreversible inhibitor of **MAO-B**.

2-It inhibits dopamine degradation by MAO-B in CNS.

3-It increases dopamine available for its receptors.

4-It slows the disease progression by reducing the formation of toxic *free radicals* produced during dopamine metabolism (**antioxidant**).

5-Selegiline is metabolized to desmethylselegiline, *Which is (antiapoptotic)*.

6-As monotherapy, may be effective in the **newly diagnosed patient with parkinsonism**.

7- Combined with levodopa / carbidopa in **later-stage parkinsonism** to:

*reduce the required dose of levodopa

*delay the onset of dyskinesias and motor fluctuations that usually accompany

long-term treatment with levodopa.

1-At high doses, selegiline may inhibit MAO-A (*hypertensive crises*).

2-May cause insomnia when taken later during the day

1-Selegiline should not be co-administered with tricyclic antidepressants, or selective serotonin reuptake inhibitors (*may cause hyperpyrexia, agitation, delirium, coma*).

<p>COMT Inhibitors (Catechol-O-methyl transferase) Inhibitors</p> <p>Entacapone</p>	<p>1-Acts peripherally and centrally to inhibit COMT enzyme required for dopamine degradation.</p> <p>2-It is used: as adjuvant to L-Dopa to:</p> <ul style="list-style-type: none"> - Decrease fluctuations - Improve response - Prolonged the ON-Time. 		<p>1-L-Dopa side effects.</p> <p>2-Orange discoloration of urine.</p>		
<p>Anticholinergic Drugs</p> <p>Benzotropine</p>	<p>1-muscarinic antagonist.</p> <p>1-Has modest anti- parkinsonian actions.</p> <p>3-used during the early stages of the disease or as an adjunct to levodopa therapy.</p> <p>4-Provide benefit in drug-induced parkinsonism (antipsychotics).</p>		<p>1-Cycloplegia, dry mouth, urinary retention, and constipation.</p> <p>2-Confusion, delirium, and hallucinations may occur at higher doses.</p>		<p>1-Prostatic hypertrophy</p> <p>2-Glaucoma</p> <p>3-Intestinal obstruction</p>

Done by: Sara ALShehri